Last €25.14 EUR
Change Today +1.05 / 4.35%
Volume 200.0
8AK On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 6:36 AM 05/24/13 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Elliot W. Ehrich M.D.

Chief Medical Officer and Senior Vice President of Research & Development, Alkermes plc
AgeTotal Calculated CompensationThis person is connected to 19 board members in 1 different organizations across 2 different industries.

See Board Relationships
53$1,975,824
As of Fiscal Year 2012

Background*

Dr. Elliot W. Ehrich, M.D. serves as the Chief Medical Officer of Alkermes plc (also known as Alkermes Inc) and has been its Senior Vice President of Research & Development since May 22, 2007. Dr. Ehrich serves as a Member of Scientific Advisory Board of Aileron Therapeutics, Inc. Dr. Ehrich served as Vice President - Science and Development at Alkermes plc until May 22, 2007. Dr. Ehrich worked as research associate at the European Molecular Biology Laboratory (EMBL) ...

Read Full Background

Corporate Headquarters*

Connaught House
Dublin, Co. Dublin 4

Ireland

Phone: 353 1 772 8000
Fax: --

Board Members Memberships*

There is no Board Members Memberships data available.

Education*

Unknown/Other Education
Stanford University
BA
Princeton University
MD
Columbia University College of Physicians & Surgeons in New York

Other Affiliations*

Annual Compensation*

Salary$435,093
Total Annual Compensation$435,093

Stock Options*

Restricted Stock Awards$271,575
All Other Compensation$8,575
Exercisable Options410,450
Exercisable Options Value$1,990,300
Unexercisable Options250,600
Unexercisable Options Value$1,218,174
Total Value of Options$3,208,473
Total Number of Options661,050

Total Compensation*

Total Annual Cash Compensation$766,168
Total Short Term Compensation$435,093
Other Long Term Compensation$280,150
Total Calculated Compensation$1,975,824
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
8AK:GR €25.14 EUR +1.05

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Jean-Jacques Bienaimé Chief Executive Officer and Director
BioMarin Pharmaceutical Inc.
$821.1K
N. Anthony Coles M.D., M.P.H.Chairman, Chief Executive Officer and President
Onyx Pharmaceuticals, Inc.
$740.0K
John H. Johnson Executive Chairman, Chief Executive Officer and President
Dendreon Corp.
$736.4K
Rajesh C. Shrotriya M.D.Chairman, Chief Executive Officer, President, Chairman of Placement Committee and Chairman of Product Acquisition Committee
Spectrum Pharmaceuticals, Inc.
$2.4M
Bruce C. Cozadd Co-Founder, Executive Chairman and Chief Executive Officer
Jazz Pharmaceuticals Public Limited Company
$722.2K
Compensation as of Fiscal Year 2012.

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ALKERMES PLC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.